

CADTH Reference List

Pharmacologic Interventions for the Treatment of Clozapine- Induced Hypersalivation

November 2021

Authors: Camille Santos, Jennifer Horton

Cite As: *Pharmacologic Interventions for the Treatment of Clozapine-Induced Hypersalivation*. (CADTH reference list). Ottawa: CADTH; 2021 Nov.

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up to date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Key Messages

- Five randomized controlled trials were identified regarding the clinical effectiveness of pharmacologic interventions for the treatment of clozapine-induced hypersalivation.
- No evidence-based guidelines were identified regarding the use of pharmacologic interventions for the treatment of clozapine-induced hypersalivation.

Research Questions

1. What is the clinical effectiveness of pharmacologic interventions for the treatment of clozapine-induced hypersalivation?
2. What are the evidence-based guidelines regarding the use of pharmacologic interventions for the treatment of clozapine-induced hypersalivation?

Methods

Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, Embase, the Cochrane Database of Systematic Reviews, the international HTA database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were clozapine, hypersalivation, and pharmacologic interventions. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English-language documents published between January 1, 2016 and November 3, 2021. Internet links were provided, where available.

Selection Criteria

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in Table 1. Full texts of study publications were not reviewed. Open-access, full-text versions of evidence-based guidelines were reviewed when abstracts were not available.

Results

Five randomized controlled trials¹⁻⁵ were identified regarding the clinical effectiveness of pharmacologic interventions for the treatment of clozapine-induced hypersalivation. No evidence-based guidelines were identified regarding the use of pharmacologic interventions for the treatment of clozapine-induced hypersalivation. Additionally, no health technology assessments, systematic reviews, and non-randomized studies were identified.

Table 1: Selection Criteria

Criteria	Description
Population	People with clozapine-induced hypersalivation
Intervention	Pharmacologic interventions (e.g., amisulpride, benzhexol, botulinum toxin, clonidine, glycopyrrolate, hyoscine, pirenzepine, propantheline, sulpride)
Comparator	Q1: Alternative pharmacologic interventions, supportive treatment, no treatment, placebo Q2: Not applicable
Outcomes	Q1: Clinical effectiveness (e.g., quality of life, symptom severity, safety [e.g., adverse events]) Q2: Recommendations regarding best practices (e.g., appropriate patient populations or clinical settings, recommended treatment strategies, strategies to mitigate harms, adverse events, and misuse)
Study designs	Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies, evidence-based guidelines

Additional references of potential interest that did not meet the inclusion criteria are provided in Appendix 1.

References

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

No literature identified.

Randomized Controlled Trials

1. Mubaslat O, Lambert T. The effect of sublingual atropine sulfate on clozapine-induced hypersalivation: a multicentre, randomised placebo-controlled trial. *Psychopharmacology*. 2020 Oct;237(10):2905-2915. [PubMed](#)
2. Segev A, Evans A, Hodsoll J, et al. Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial. *Int Clin Psychopharmacol*. 2019 03;34(2):101-107. [PubMed](#)
3. Sheikhoonesi F, Zarghami M, Hendoi N, Azari P, Cherati JY, Rezapour M. Comparing the impact of atropine drops and amitriptyline tablets in treatment of clozapine-induced sialorrhea: a randomized double-blind placebo controlled clinical trial. *Acta Medica Iranica*. 2018 24 Dec;56(12):757-763.
4. Man WH, Colen-de Koning JC, Schulte PF, et al. The effect of glycopyrrolate on nocturnal sialorrhea in patients using clozapine: a randomized, crossover, double-blind, placebo-controlled trial. *J Clin Psychopharmacol*. 2017 Apr;37(2):155-161. [PubMed](#)
5. Kreinin A, Miodownik C, Mirkin V, et al. Double-blind, randomized, placebo-controlled trial of metoclopramide for hypersalivation associated with clozapine. *J Clin Psychopharmacol*. 2016 Jun;36(3):200-205. [PubMed](#)

Non-Randomized Studies

No literature identified.

Guidelines and Recommendations

No literature identified.

Appendix 1: References of Potential Interest

Systematic Review and Meta-Analyses

Not Specific to Clozapine-Induced Hypersalivation

6. Dashtipour K, Bhidayasiri R, Chen JJ, Jabbari B, Lew M, Torres-Russotto D. RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. *J Clin Mov Disord*. 2017; 4:9. [PubMed](#)

Unclear Comparator

7. Chen SY, Ravindran G, Zhang Q, Kisely S, Siskind D. Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. *CNS Drugs*. 03 2019; 33(3): 225-238. [PubMed](#)

Methods Not Specified

8. Van der Poorten T, De Hert M. The sublingual use of atropine in the treatment of clozapine-induced sialorrhea: a systematic review. *Clin Case Rep*. 2019 Nov;7(11):2108-2113. [PubMed](#)

Randomized Controlled Trials

Not Specific to Clozapine-Induced Hypersalivation

9. Isaacson SH, Ondo W, Jackson CE, et al. Safety and efficacy of rimabotulinumtoxinb for treatment of sialorrhea in adults: a randomized clinical trial. *JAMA Neurol*. 2020 04 01;77(4):461-469. [PubMed](#)

Alternative Comparator

10. Takeuchi I, Hanya M, Uno J, Fujita K, Kamei H. Effectiveness of the repeated administration of scopolamine ointment on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: a preliminary study. *Asia Pac Psychiatry*. 2017 Dec;9(4). [PubMed](#)

Non-Randomized Studies

Not Specific to Clozapine-Induced Hypersalivation

11. Toulemonde P, Maltezeanu A, Broucqsault H, Fayoux P. Tolerance of salivary gland botulinum toxin A injection under local anesthesia for the treatment of sialorrhea in children: an observational study. *Eur Ann Otorhinolaryngol Head Neck Dis*. 2021 Jun 30;30:30. [PubMed](#)
12. Abboud WA, Nadel S, Hassin-Baer S, Arad A, Dobriyan A, Yahalom R. Ultrasound-guided botulinum toxin injections into the salivary glands for the treatment of drooling. *Isr Med Assoc J*. 2019 Feb;21(2):116-119. [PubMed](#)
13. Taib BG, Williams SP, Sood S, Ung K, Nixon PP, Sharma R. Treatment of sialorrhoea with repeated ultrasound-guided injections of botulinum toxin A into the parotid and submandibular glands. *Br J Oral Maxillofac Surg*. 2019 06;57(5):442-448. [PubMed](#)
14. Shariat-Madar B, Chun RH, Sulman CG, Conley SF. Safety of ultrasound-guided botulinum toxin injections for sialorrhea as performed by pediatric otolaryngologists. *Otolaryngol Head Neck Surg*. 2016 05;154(5):924-927. [PubMed](#)

Not Specific to Pharmacological Treatment

15. Weitzman RE, Kawai K, Nuss R, Hughes A. A 10-year retrospective review of botulinum toxin injections and surgical management of sialorrhea. *Cureus*. 2020 May 01;12(5):e7916. [PubMed](#)

Additional References

16. Vova JA, Green MM, Brandenburg JE, et al. A Consensus statement on the use of botulinum toxin in pediatric patients. *Pm R* 2021 Sep 23;23:23. [PubMed](#)
17. Gupta S, Khastgir U, Croft M, Roshny S. Management of clozapine-induced sialorrhoea. *BJPsych Advances*. 2020 01 Mar;26(2):106-10.
18. Appendix 16 – clozapine-related hypersalivation. V03-Apr 19 (PPT-PGN-05 – safe prescribing of clozapine – (NTW(C) 38 - policy on pharmacological therapies). Northumberland (GB):Northumberland, Tyne and Wear NHS Foundation Trust; 2019. <https://www.cntw.nhs.uk/content/uploads/2019/04/PPT-PGN-05-App16-Clozapine-related-hypersalivation-V03-Apr-19.pdf> Accessed 2021 Nov 5.
19. Haastrup MB, Henriksen DP, Christensen MMH. Drug-induced sialorrhoea. *Adverse Drug React Bull*. 2018 01 Dec;313(1):1211-1214.